West Pharmaceutical Services Past Earnings Performance
Past criteria checks 5/6
West Pharmaceutical Services has been growing earnings at an average annual rate of 19.7%, while the Life Sciences industry saw earnings growing at 19.5% annually. Revenues have been growing at an average rate of 12% per year. West Pharmaceutical Services's return on equity is 21.2%, and it has net margins of 19.4%.
Key information
19.7%
Earnings growth rate
19.6%
EPS growth rate
Life Sciences Industry Growth | 19.5% |
Revenue growth rate | 12.0% |
Return on equity | 21.2% |
Net Margin | 19.4% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How West Pharmaceutical Services makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 2,929 | 569 | 355 | 69 |
31 Dec 23 | 2,950 | 593 | 354 | 68 |
30 Sep 23 | 2,927 | 559 | 299 | 66 |
30 Jun 23 | 2,866 | 519 | 326 | 63 |
31 Mar 23 | 2,884 | 552 | 319 | 61 |
31 Dec 22 | 2,887 | 586 | 316 | 59 |
30 Sep 22 | 2,909 | 631 | 377 | 56 |
30 Jun 22 | 2,929 | 686 | 352 | 56 |
31 Mar 22 | 2,881 | 684 | 362 | 55 |
31 Dec 21 | 2,832 | 662 | 356 | 53 |
30 Sep 21 | 2,681 | 613 | 340 | 52 |
30 Jun 21 | 2,523 | 519 | 310 | 51 |
31 Mar 21 | 2,326 | 423 | 308 | 48 |
31 Dec 20 | 2,147 | 346 | 301 | 47 |
30 Sep 20 | 2,037 | 312 | 291 | 44 |
30 Jun 20 | 1,945 | 286 | 297 | 41 |
31 Mar 20 | 1,888 | 261 | 277 | 40 |
31 Dec 19 | 1,840 | 242 | 273 | 39 |
30 Sep 19 | 1,792 | 230 | 262 | 39 |
30 Jun 19 | 1,767 | 229 | 259 | 39 |
31 Mar 19 | 1,745 | 219 | 258 | 41 |
31 Dec 18 | 1,717 | 207 | 256 | 40 |
30 Sep 18 | 1,711 | 155 | 257 | 40 |
30 Jun 18 | 1,677 | 151 | 256 | 39 |
31 Mar 18 | 1,627 | 133 | 248 | 38 |
31 Dec 17 | 1,599 | 151 | 243 | 39 |
30 Sep 17 | 1,566 | 190 | 245 | 39 |
30 Jun 17 | 1,544 | 176 | 242 | 39 |
31 Mar 17 | 1,535 | 182 | 243 | 38 |
31 Dec 16 | 1,509 | 144 | 238 | 37 |
30 Sep 16 | 1,487 | 138 | 241 | 37 |
30 Jun 16 | 1,454 | 102 | 238 | 37 |
31 Mar 16 | 1,426 | 85 | 246 | 36 |
31 Dec 15 | 1,400 | 96 | 243 | 34 |
30 Sep 15 | 1,390 | 94 | 240 | 32 |
30 Jun 15 | 1,401 | 123 | 241 | 33 |
31 Mar 15 | 1,411 | 133 | 228 | 35 |
31 Dec 14 | 1,421 | 127 | 229 | 37 |
30 Sep 14 | 1,414 | 119 | 230 | 39 |
30 Jun 14 | 1,400 | 115 | 230 | 39 |
31 Mar 14 | 1,376 | 108 | 232 | 39 |
31 Dec 13 | 1,368 | 112 | 235 | 38 |
30 Sep 13 | 1,347 | 110 | 234 | 37 |
30 Jun 13 | 1,309 | 98 | 231 | 35 |
Quality Earnings: W2ST34 has high quality earnings.
Growing Profit Margin: W2ST34's current net profit margins (19.4%) are higher than last year (19.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: W2ST34's earnings have grown by 19.7% per year over the past 5 years.
Accelerating Growth: W2ST34's earnings growth over the past year (3%) is below its 5-year average (19.7% per year).
Earnings vs Industry: W2ST34 earnings growth over the past year (3%) exceeded the Life Sciences industry 0.2%.
Return on Equity
High ROE: W2ST34's Return on Equity (21.2%) is considered high.